Cytochroma Inc. Announces Initiation of Phase II Clinical Trial of CTA018 for Chronic Kidney Disease Patients

MARKHAM, ON, Oct. 23 /CNW/ - Cytochroma today announced that it has initiated a Phase II clinical trial of CTA018 Injection, the Company's product candidate for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD). The Phase II clinical trial is an open label, dose escalating pharmacokinetic, pharmacodynamic, efficacy and safety study of CTA018 Injection in CKD patients with SHPT undergoing hemodialysis.